No abstract

A new cerebroside (2R)-2-hydroxy-N-[(Z,2S,3S,4R)-1-O-β-D-glucopyranosyl-3,4-dihydroxynonadec-8-en-2-yl] nonacosanamide (1) was isolated from the wood of roots of V. paradoxa along with six known compounds including catechin (2), quercetin (3), spinasterol 3-O-β-D-glucopyranoside (6), gallic acid (7) and a mixture of β-sitosterol (4) and stigmasterol (5). The structure of the new compound was established by 1D (1 H and 13 C NMR) and 2D NMR (COSY and HSQC) spectroscopy, extensive mass spectrometry and by comparison with published data. The antibacterial, α-glucosidase and alkaline phosphatase (AP) inhibitory activities of all the pure compounds were evaluated. The antibacterial activities were evaluated against three gram negative bacteria (Escherichia coli; Salmonella typhimurium and Pseudomonas aeruginosa) while APs inhibitory activities were evaluated on h-TNAP and h-IAP. Significant antibacterial activity was recorded for quercetin (3) against P. aeruginosa. Most of the compounds except 1 and 6 were found to be inhibitors of α-glucosidase. The highest inhibitory potential being recorded for quercetin (3) with IC 50 value of 4.30 ± 0.01 µM, 55 fold higher than the standard drug acarbose (IC 50 =234.6 ± 2.01 µM). All tested compounds exhibited moderate inhibitory activities against APs. h-TNAP inhibitory values were ranged between 41.24 ± 1.33 µM and 312.54 ± 6.44 µM while h-IAP inhibitory values were in the range of 47.95 ± 0.35 µM and 777.47 ± 18.55 µM. Quercetin (3) was found to be the most active h-IAP inhibitor (IC 50 =47.95 ± 0.35 mM), whereas, spinasterol 3-O-β-D-glucopyranoside (6) was found to be the most active h-TNAP inhibitor (IC 50 =41.24 ± 1.33 mM). The new compound (1) showed moderate inhibition on h-IAP (78.11 ± 3.70 µM) and on h-TNAP (88.84 ± 2.70 µM).

The development and spread of resistance to currently available antibiotics is a major drawback in the treatment of microbial infections. Salmonellosis for example remains among the most common cause of morbidity and mortality in developing countries. This study aimed to evaluate the antisalmonellal potential of extracts, fractions, isolated compounds and semi-synthetic flavonoids from Tristemma hirtum P. Beauv. Bioguided fractionation by column chromatography of the EtOAc and n-BuOH fractions led to the isolation of eleven compounds including two new esterified glucuronide flavonoids namely: luteolin-3′-O-β-D-glucuronopyranosylbutyl ester (1), a mixture of compound 1 and quercetin-3-O-β-D-glucuronopyranosylbutyl ester (2). Chemical transformation mainly based on the prenylation of 6-hydroxyapigenin-7-O-β-D-glucopyranoside (5) afforded four new semi-synthetic flavonoid derivatives namely: 6, 4'-O-diprenylapigenin-7-O-β-D-glucopyranoside (5a), 8-Cprenyl-6, 4'-O-diprenylapigenin-7-O-β-D-glucopyranoside (5b), 8-C-prenyl-4'-O-prenylapigenin-7-O-β-D-glucopyranoside (5c), 4'-O-prenylapigenin-7-O-β-D-glucopyranoside (5d). The chemical structures of these compounds were assigned using NMR techniques, mass spectrometry and by comparison of their data with reported ones. The antisalmonellal activity was assessed by determining the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) using serial microdilution methods. The results showed that the MeOH extract and EtOAc fraction were active against all the bacteria tested with MICs ranging from 24 to 1536 µg/mL. Seven isolated compounds and three semi-synthetic compounds tested showed MIC values ranging from 16 to 256 µg/mL. Compounds 1, 3, 5a, 5c and 11 displayed the most potent antisalmonellal properties but were generally less potent than those of reference drugs. The activity of extracts and isolated compounds could be used as the starting point for the development of alternative phytodrugs against salmonellosis.